Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Phase 1/2 clinical trial in patients with advanced solid tumors that have progressed on anti-PD-1/PD-L1 therapy to evaluate APX005M in combination with cabiralizumab and Opdivo
Study to enroll metastatic non-small cell lung cancer (NSCLC), metastatic me... Biopharmaceuticals, Oncology Apexigen, cabiralizumab, Opdivo, NSCLC, melanoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Pharmaceuticals | Skin Cancer | Study | Yale